Apogee lands up to $1.3B from Blackstone for zumilokibart

Apogee Therapeutics said on May 27, 2026, that it has struck a strategic financing collaboration with Blackstone Life Sciences worth up to $1.3 billion to support Phase 3 development and potential commercialization of zumilokibart, its anti-IL-13 antibody for moderate-to-severe atopic dermatitis. The package includes an initial $100 million upfront payment under a revenue participation agreement, milestone-based tranches that could bring the synthetic royalty financing to as much as $800 million, and a separate option for up to $500 million in debt financing by mutual agreement. The announcement came alongside positive 16-week Phase 2 APEX Part B data, which Apogee said support moving the mid-dose regimen into Phase 3 in the second half of 2026, pending regulatory interactions. (globenewswire.com)

Why it matters: For veterinary professionals, this is mostly a business-and-pipeline signal rather than a practice-changing development. But it’s still worth watching because large, non-dilutive financing tied to late-stage milestones suggests investors see a clearer path for zumilokibart in a crowded immunology market, and Apogee now says the funding could support development through commercialization in atopic dermatitis, with expansion plans in asthma and eosinophilic esophagitis as well. The Phase 2 dataset also reinforces continued industry interest in less-frequent biologic dosing for chronic inflammatory disease, a theme that can influence expectations across dermatology and immunology more broadly. (globenewswire.com)

What to watch: The next key milestones are Apogee’s regulatory discussions, Phase 3 trial starts in the second half of 2026, and whether it unlocks the next Blackstone funding tranches tied to enrollment, data, and eventual FDA approval. (globenewswire.com)